D. Boral Capital reissued their buy rating on shares of Context Therapeutics (NASDAQ:CNTX - Free Report) in a research report released on Tuesday,Benzinga reports. The firm currently has a $9.00 price target on the stock.
Other analysts have also recently issued reports about the stock. Citizens Jmp raised shares of Context Therapeutics to a "strong-buy" rating in a report on Wednesday, January 8th. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 target price on shares of Context Therapeutics in a report on Friday, March 21st. William Blair initiated coverage on Context Therapeutics in a research report on Monday, April 21st. They issued an "outperform" rating for the company. Finally, JMP Securities started coverage on Context Therapeutics in a research note on Wednesday, January 8th. They set an "outperform" rating and a $4.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $6.17.
Check Out Our Latest Analysis on CNTX
Context Therapeutics Stock Up 0.8 %
CNTX traded up $0.01 during mid-day trading on Tuesday, reaching $0.87. 30,000 shares of the company traded hands, compared to its average volume of 300,208. The company's fifty day moving average price is $0.78 and its 200-day moving average price is $1.16. The stock has a market capitalization of $78.01 million, a P/E ratio of -0.96 and a beta of 2.18. Context Therapeutics has a 52-week low of $0.55 and a 52-week high of $2.75.
Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. As a group, sell-side analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.
Institutional Trading of Context Therapeutics
Institutional investors have recently made changes to their positions in the business. Jane Street Group LLC bought a new position in Context Therapeutics in the 4th quarter worth approximately $29,000. Citadel Advisors LLC purchased a new position in Context Therapeutics during the fourth quarter valued at $31,000. Shay Capital LLC purchased a new position in Context Therapeutics during the fourth quarter valued at $52,000. Clear Harbor Asset Management LLC lifted its stake in Context Therapeutics by 60.6% in the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock worth $61,000 after purchasing an additional 21,804 shares in the last quarter. Finally, Landscape Capital Management L.L.C. bought a new position in shares of Context Therapeutics during the 4th quarter valued at about $94,000. Hedge funds and other institutional investors own 14.03% of the company's stock.
Context Therapeutics Company Profile
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Read More

Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.